A review of transthyretin cardiac amyloidosis

Abstract

Transthyretin cardiac amyloidosis is a progressive disease known to cause heart failure, conduction anomalies, and arrythmias. Due to poor outcomes and mortality from severe cardiomyopathy, prevalence and incident rates are often underreported. As global longevity is increasing and rates of amyloidosis are also increasing, there is a need to improve diagnostic and therapeutic interventions. Previously, symptom management and transplantation were the mainstay of treatment for heart failure symptoms, but studies using RNAi and siRNA technologies have shifted the paradigm of therapeutic strategy in amyloid cardiomyopathy management. Additionally, early detection and clinical monitoring with numerous imaging and non-imaging techniques are being increasingly investigated. Here, we review the epidemiology, pathophysiology, diagnosis, and management of transthyretin amyloid cardiomyopathy.

The Importance of Ultrasound-Guided Synovial Biopsy in the Workup of Seronegative Inflammatory Arthritis: A Case Report

“…A review of the literature showed that carpal tunnel syndrome is a common early clinical feature of cardiac TTR amyloidosis, but few reports describe synovitis and elevated CRP associated with TTR amyloidosis [4,6,7]. The finding of moderate synovitis with moderate Doppler signal in the wrist, which is strongly associated with active inflammatory disease, is an uncommon feature of cardiac TTR amyloidosis.…”